Basking Ridge, NJ, United States of America

Ho-Wah Hui

USPTO Granted Patents = 24 (Patent Applications = 7)

CIPO Patents = 4

EPO Patents = 8 (Patent Applications = 7)

Average Co-Inventor Count = 3.6

ph-index = 5

Forward Citations = 114(Granted Patents)

Location History:

Vernon Hills, IL (US) (1992)
Libertyville, IL (US) (2000 - 2013)
Somerset County, NJ (US) (2015)
Basking Ridge, NJ (US) (2016 - 2024)

Company Filing History:

Abbott Laboratories Corporation

patents

1 out of 169

Signal Pharmaceuticals, Inc.

patents

Years Active: 1992-2024

Loading Chart...

24 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11883389 - Formulations of 2-(4-chlorophenyl)-N-((2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide (2024-01-30),

2. 11406629 - Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereof (2022-08-09),

3. 11129821 - Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide (2021-09-28),

4. 10835522 - Solid forms comprising 4-amino-2-(2,6- dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereof (2020-11-17),

5. 10449187 - Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide (2019-10-22),

6. 10376503 - Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereof (2019-08-13),

7. 10052315 - Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide (2018-08-21),

8. 9974780 - Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereof (2018-05-22),

9. 9968627 - Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof (2018-05-15),

10. 9884042 - Formulations of cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide (2018-02-06),

11. 9808450 - Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof (2017-11-07),

12. 9795650 - Romidepsin formulations and uses thereof (2017-10-24),

13. 9782451 - Romidepsin formulations and uses thereof (2017-10-10),

14. 9757355 - Oral dosage forms of cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide (2017-09-12),

15. 9695146 - Solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer, compositions and methods of use thereof (2017-07-04),

Title: The Innovative Contributions of Ho-Wah Hui

Introduction

Ho-Wah Hui, based in Basking Ridge, NJ, is a prolific inventor with an impressive portfolio of 21 patents. His contributions primarily focus on the development of pharmaceutical formulations and methods for treating various medical conditions, particularly cancer.

Latest Patents

Among his latest inventions, Hui has made significant strides with formulations designed for the compound 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide. These formulations are lyophilized and aim to optimize the delivery and efficacy of the compound, which is crucial in cancer treatment. Furthermore, he has developed solid forms containing 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, which also come with a coformer, enhancing their therapeutic potential against various disorders.

Career Highlights

Throughout his career, Ho-Wah Hui has worked with reputable organizations such as Celgene Corporation and Signal Pharmaceuticals, Inc. His innovative spirit and dedication to pharmaceutical advancements have paved the way for numerous developments that could significantly impact patient care.

Collaborations

In the course of his career, Hui has collaborated with notable colleagues, including Kevin Joseph Klopfer and G Patrick Stahly. These partnerships have fostered a rich environment for innovation and have led to the successful creation of several patents that address pressing healthcare needs.

Conclusion

Ho-Wah Hui's contributions to the field of pharmaceuticals exemplify how innovation can lead to improvements in treatment strategies, particularly in oncology. With a growing number of patents and a commitment to research and development, his work continues to inspire and pave the way for future advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.